Modality
mRNA
MOA
MDM2i
Target
CDK4/6
Pathway
Proteasome
RettWM
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
Jun 2024
→ Dec 2030
Phase 1Current
NCT07030537
2,638 pts·Rett
2024-06→2030-12·Recruiting
2,638 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-12-124.7y awayInterim· Rett
Trial Timeline
Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Recruit…
Catalysts
Interim
2030-12-12 · 4.7y away
Rett
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07030537 | Phase 1 | Rett | Recruiting | 2638 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 | |
| 180-6098 | Innovent Bio | Phase 1 | ALK |